PDS Biotechnology Corporation
NASDAQ:PDSB
Overview | Financials
Company Name | PDS Biotechnology Corporation |
Symbol | PDSB |
Currency | USD |
Price | 3.28 |
Market Cap | 120,768,944 |
Dividend Yield | 0% |
52-week-range | 2.53 - 6.85 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Frank K. Bedu-Addo Ph.D. |
Website | https://www.pdsbiotech.com |
An error occurred while fetching data.
About PDS Biotechnology Corporation
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD